New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
06:35 EDTISISIsis may have most attractive pipeline in biotech, says Piper Jaffray
Piper Jaffray believes Isis Pharmaceuticals' wholly owned and partnered assets could represent the most attractive and undervalued pipeline in biotech. The firm reiterates an Overweight rating on the stock with a $42 price target following the company's R&D day.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 13, 2014
07:12 EDTISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
09:00 EDTISISOn The Fly: Pre-market Movers
Subscribe for More Information
05:22 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 study
Subscribe for More Information
October 9, 2014
07:02 EDTISISIsis Pharmaceuticals receives $18M milestone payment from GlaxoSmithKline
Subscribe for More Information
October 8, 2014
11:10 EDTISISOptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use